Advertisement

Topics

FDA Approves Ironwood Pharmaceutical's Duzallo to Treat Hyperuricemia in Uncontrolled Gout Patients

15:18 EDT 21 Aug 2017 | Drug Discovery Development

This fixed-dose combination provides a dual mechanism of action in a single tablet that can address both underlying causes of hyperuricemia.
Contributed Author: 
Ironwood Pharmaceuticals
Topics: 

Original Article: FDA Approves Ironwood Pharmaceutical's Duzallo to Treat Hyperuricemia in Uncontrolled Gout Patients

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Ironwood Pharmaceutical's Duzallo to Treat Hyperuricemia in Uncontrolled Gout Patients"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Gout
According to the National Arthritis Data Workgroup, an estimated 6 million people in the United States report having experienced gout at some point in their lives. In fact, gout is the most common form of inflammatory arthritis in men over the age of 40....